Kestra Medical director granted 75,681 RSUs

Webster Brian Daniel reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Webster Brian Daniel reported acquisition or exercise transactions in this Form 4 filing.

Kestra Medical Technologies director and officer Brian Daniel Webster received an equity grant of 75,681 restricted stock units (RSUs), each settling into one common share at no purchase price. These RSUs vest over three years, with one-third vesting on each anniversary of June 3, 2026, contingent on his continued service. Following this grant, Webster is reported as beneficially owning 410,467 common shares, showing his overall equity stake including this new award.

Insider Trade Summary

Grant/Award: 75,681 shares

Grant/Award 1 txn

Insider Webster Brian Daniel

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Common Shares	75,681	$0.00	$0.00

Holdings After Transaction: Common Shares — 410,467 shares (Direct)

Footnotes (1)

1. F1. Represents restricted stock units ("RSU") that entitle the Reporting Person to receive, at settlement, one common share of Kestra Medical Technologies, Ltd. Subject to the Reporting Person's continued service, the RSUs will vest over three years, with 1/3 vesting on each anniversary of June 3, 2026.

Key Figures

RSUs granted: 75,681 units Grant price: $0.0000 per unit Total shares after grant: 410,467 shares +2 more

5 metrics

RSUs granted 75,681 units Restricted stock units awarded on June 3, 2026

Grant price $0.0000 per unit RSU award at no cash cost to insider

Total shares after grant 410,467 shares Common shares beneficially owned following the RSU award

Vesting period 3 years RSUs vest over three years, subject to continued service

Annual vesting tranche 1/3 each year One-third vests on each anniversary of June 3, 2026

Key Terms

restricted stock units ("RSU"), vest over three years, beneficially owns

3 terms

restricted stock units ("RSU") financial

"Represents restricted stock units ("RSU") that entitle the Reporting Person to receive, at settlement, one common share"

vest over three years financial

"Subject to the Reporting Person's continued service, the RSUs will vest over three years"

beneficially owns financial

"total_shares_following_transaction": "410467.0000"

Beneficially owns means a person or entity enjoys the economic benefits and control of a security even if the legal title or registration is held in another name. Think of it like having the keys and profits from a car that is registered to a friend: you use it, benefit from it, and make decisions about it even though the official paperwork lists someone else. For investors, this matters because it reveals who truly controls shares, affects voting power, potential conflicts of interest, and regulatory disclosure obligations.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did KMTS director Brian Daniel Webster report?

Brian Daniel Webster reported an award of 75,681 restricted stock units in Kestra Medical Technologies. These RSUs were granted at no cash cost and will convert into common shares as they vest over time, increasing his overall equity-based compensation position.

How many Kestra Medical (KMTS) shares does Brian Daniel Webster hold after this Form 4?

After the reported RSU grant, Brian Daniel Webster beneficially owns 410,467 common shares of Kestra Medical Technologies. This figure includes the newly awarded restricted stock units that will settle into common shares as they vest over the three-year schedule described.

What are the vesting terms of Brian Daniel Webster’s KMTS RSU grant?

The 75,681 Kestra Medical RSUs vest over three years, with one-third vesting on each anniversary of June 3, 2026. Vesting is conditioned on Webster’s continued service, meaning the units convert into common shares gradually as he remains with the company.

Was Brian Daniel Webster’s KMTS RSU grant an open-market purchase or a compensation award?

The transaction is classified as a grant or award acquisition, not an open-market purchase. The RSUs were granted at a transaction price of $0.0000 per unit, indicating equity-based compensation rather than shares bought on the public market by the insider.

Does the KMTS Form 4 show any insider share sales by Brian Daniel Webster?

The Form 4 shows only an acquisition via RSU grant and no reported sales. The transaction summary reflects one acquisition and zero dispositions, indicating this filing solely documents an equity award rather than any sale or reduction in his Kestra Medical share position.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/04/2026 - 06:35 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Webster Brian Daniel

(Last) (First) (Middle)

3933 LAKE WASHINGTON BLVD NE, SUITE 200

(Street)

KIRKLAND WASHINGTON 98033

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KESTRA MEDICAL TECHNOLOGIES, LTD. [ KMTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	06/03/2026		A		75,681(1)	A	$0.00	410,467	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units ("RSU") that entitle the Reporting Person to receive, at settlement, one common share of Kestra Medical Technologies, Ltd. Subject to the Reporting Person's continued service, the RSUs will vest over three years, with 1/3 vesting on each anniversary of June 3, 2026.

Remarks:

President and Chief Executive Officer

	/s/ Brian Daniel Webster	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)